BR112022020410A2 - Anticorpos anti-phf-tau e usos dos mesmos - Google Patents
Anticorpos anti-phf-tau e usos dos mesmosInfo
- Publication number
- BR112022020410A2 BR112022020410A2 BR112022020410A BR112022020410A BR112022020410A2 BR 112022020410 A2 BR112022020410 A2 BR 112022020410A2 BR 112022020410 A BR112022020410 A BR 112022020410A BR 112022020410 A BR112022020410 A BR 112022020410A BR 112022020410 A2 BR112022020410 A2 BR 112022020410A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibodies
- phf
- tau antibodies
- tau
- taupathies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063007118P | 2020-04-08 | 2020-04-08 | |
| US202063026387P | 2020-05-18 | 2020-05-18 | |
| PCT/IB2021/052890 WO2021205359A1 (en) | 2020-04-08 | 2021-04-07 | Anti-phf-tau antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022020410A2 true BR112022020410A2 (pt) | 2023-01-03 |
Family
ID=78023121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022020410A BR112022020410A2 (pt) | 2020-04-08 | 2021-04-07 | Anticorpos anti-phf-tau e usos dos mesmos |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20230151083A1 (https=) |
| EP (1) | EP4132569A4 (https=) |
| JP (1) | JP2023521763A (https=) |
| KR (1) | KR20220166308A (https=) |
| CN (1) | CN115697393A (https=) |
| AU (1) | AU2021251486A1 (https=) |
| BR (1) | BR112022020410A2 (https=) |
| CA (1) | CA3179914A1 (https=) |
| CL (1) | CL2022002766A1 (https=) |
| CO (1) | CO2022015737A2 (https=) |
| CR (1) | CR20220505A (https=) |
| DO (1) | DOP2022000218A (https=) |
| EC (1) | ECSP22078815A (https=) |
| IL (1) | IL297231A (https=) |
| JO (1) | JOP20220255A1 (https=) |
| MX (1) | MX2022012628A (https=) |
| PE (1) | PE20230385A1 (https=) |
| PH (1) | PH12022553035A1 (https=) |
| TW (1) | TW202204402A (https=) |
| WO (1) | WO2021205359A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3093200A1 (en) | 2018-03-05 | 2019-09-12 | Janssen Pharmaceutica Nv | Anti-phf-tau antibodies and uses thereof |
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| AU2023232448A1 (en) * | 2022-03-11 | 2024-10-24 | Janssen Pharmaceutica Nv | Multispecific antibodies and uses thereof |
| CA3254442A1 (en) * | 2022-03-11 | 2023-09-14 | Janssen Pharmaceutica Nv | MULTISPECIFIC ANTIBODIES AND THEIR USES |
| KR20250069606A (ko) | 2022-09-15 | 2025-05-19 | 보이저 테라퓨틱스, 인크. | 타우 결합 화합물 |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX350311B (es) * | 2011-12-20 | 2017-09-01 | Janssen Biotech Inc | Anticuerpos anti-phf-tau y sus usos. |
| WO2016112078A2 (en) * | 2015-01-08 | 2016-07-14 | Janssen Biotech, Inc. | Anti-phf-tau antibodies and their uses |
| US10344081B2 (en) * | 2015-07-06 | 2019-07-09 | Ucb Biopharma Sprl | Tau-binding antibodies |
| CN106939047B (zh) * | 2016-01-04 | 2021-08-31 | 江苏怀瑜药业有限公司 | 一种pd-l1抗体及其制备方法 |
| TWI771389B (zh) * | 2017-03-16 | 2022-07-21 | 美商健生生物科技公司 | 抗phf-tau抗體及其用途 |
| US10591492B2 (en) * | 2018-03-05 | 2020-03-17 | Janssen Pharmaceutica Nv | Assays to detect neurodegeneration |
| CA3179922A1 (en) * | 2020-04-08 | 2021-10-14 | Janssen Biotech, Inc. | Anti-cd98 antibodies and uses thereof |
| CN121754667A (zh) * | 2020-04-08 | 2026-03-31 | 阿里亚达治疗公司 | 用于血脑屏障递送的组合物和方法 |
-
2021
- 2021-04-07 US US17/917,916 patent/US20230151083A1/en active Pending
- 2021-04-07 KR KR1020227038806A patent/KR20220166308A/ko active Pending
- 2021-04-07 WO PCT/IB2021/052890 patent/WO2021205359A1/en not_active Ceased
- 2021-04-07 CN CN202180041278.1A patent/CN115697393A/zh active Pending
- 2021-04-07 EP EP21783771.5A patent/EP4132569A4/en not_active Withdrawn
- 2021-04-07 MX MX2022012628A patent/MX2022012628A/es unknown
- 2021-04-07 CA CA3179914A patent/CA3179914A1/en active Pending
- 2021-04-07 PE PE2022002218A patent/PE20230385A1/es unknown
- 2021-04-07 PH PH1/2022/553035A patent/PH12022553035A1/en unknown
- 2021-04-07 BR BR112022020410A patent/BR112022020410A2/pt unknown
- 2021-04-07 CR CR20220505A patent/CR20220505A/es unknown
- 2021-04-07 JP JP2022561415A patent/JP2023521763A/ja active Pending
- 2021-04-07 AU AU2021251486A patent/AU2021251486A1/en not_active Abandoned
- 2021-04-07 IL IL297231A patent/IL297231A/en unknown
- 2021-04-08 TW TW110112656A patent/TW202204402A/zh unknown
-
2022
- 2022-10-06 JO JOJO/P/2022/0255A patent/JOP20220255A1/ar unknown
- 2022-10-06 CL CL2022002766A patent/CL2022002766A1/es unknown
- 2022-10-07 EC ECSENADI202278815A patent/ECSP22078815A/es unknown
- 2022-10-07 DO DO2022000218A patent/DOP2022000218A/es unknown
- 2022-10-31 CO CONC2022/0015737A patent/CO2022015737A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2022002766A1 (es) | 2023-04-21 |
| CO2022015737A2 (es) | 2023-02-27 |
| CA3179914A1 (en) | 2021-10-14 |
| WO2021205359A1 (en) | 2021-10-14 |
| AU2021251486A1 (en) | 2022-12-08 |
| CN115697393A (zh) | 2023-02-03 |
| EP4132569A1 (en) | 2023-02-15 |
| PE20230385A1 (es) | 2023-03-06 |
| IL297231A (en) | 2022-12-01 |
| EP4132569A4 (en) | 2024-07-31 |
| US20230151083A1 (en) | 2023-05-18 |
| MX2022012628A (es) | 2023-01-11 |
| ECSP22078815A (es) | 2022-11-30 |
| PH12022553035A1 (en) | 2024-05-13 |
| JOP20220255A1 (ar) | 2022-10-06 |
| KR20220166308A (ko) | 2022-12-16 |
| DOP2022000218A (es) | 2023-04-30 |
| JP2023521763A (ja) | 2023-05-25 |
| TW202204402A (zh) | 2022-02-01 |
| CR20220505A (es) | 2023-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022020410A2 (pt) | Anticorpos anti-phf-tau e usos dos mesmos | |
| MX2024015440A (es) | Anticuerpos anti-phf-tau y usos de estos | |
| BR112021022089A2 (pt) | Materiais e métodos para modulação da imunidade mediada por células t | |
| BR112022014667A2 (pt) | Anticorpos de domínio único de cd28 e construtos multivalentes e multiespecíficos dos mesmos | |
| BR112022003147A2 (pt) | Novos anticorpos anti-cldn18.2 | |
| BR112022015374A2 (pt) | Anticorpos contra sars-cov-2 e métodos de uso dos mesmos | |
| BR112018076281A2 (pt) | imunocitocina, uso de uma imunocitocina, método, composição farmacêutica, método para tratar uma doença proliferativa em um animal, ácido nucleico, vetor, hospedeiro e anticorpo ou fragmento do mesmo | |
| BR112016013347A8 (pt) | anticorpo monoclonal humano neutralizante anti-il-33,composição farmacêutica,inibidor da expressão de citocinas,epitopo,molécula de ácido nucleico,vetor,célula hospedeira,método de produção e uso dos mesmos. | |
| BR112018003326A2 (pt) | anticorpos de ligação de linfopoietina estromal tímica (tslp) e métodos de uso dos anticorpos | |
| BR112023019546A2 (pt) | Anticorpos anti-tau e usos dos mesmos | |
| BR112018068340A2 (pt) | imunoglobulinas de ligação ao tgfss1 e usos destas | |
| BR112021016398A2 (pt) | Anticorpos cd33 e métodos de uso dos mesmos para tratar o câncer | |
| JOP20190187A1 (ar) | مترافقات عقار جسم مضاد لـ ccr7 | |
| BR112021008060A2 (pt) | Polipeptídeo, anticorpo anti-ctla4 ou fragmento de anticorpo, imunoconjugado, composição farmacêutica, dose única de composição farmacêutica, método de tratar câncer, e, kit para diagnóstico ou tratamento | |
| BR112022000216A2 (pt) | Anticorpos direcionados a dll3 e usos dos mesmos | |
| BR112023016574A2 (pt) | Composições de anticorpo anti-tl1a e métodos de tratamento no pulmão | |
| BR112021009275A2 (pt) | Anticorpo humanizado anti-sirp alfa ou um fragmento de ligação a antígeno do mesmo, composição farmacêutica, molécula de ácido nucleico, e, célula hospedeira. | |
| BR112022003635A2 (pt) | Anticorpo anti-vsig4 ou fragmento de ligação ao antígeno e seu uso | |
| BR112023019205A2 (pt) | Anticorpos humanizados contra tau de filamento helicoidal pareado e usos dos mesmos | |
| EA202092088A1 (ru) | Антитела анти-phf-тау и их применение | |
| BR112021013397A2 (pt) | Anticorpos anti-tigit | |
| BR112018072118A2 (pt) | anticorpos de interferona beta e usos dos mesmos | |
| BR112023020622A2 (pt) | Anticorpo anti-masp2, fragmento de ligação ao antígeno do mesmo e uso médico do mesmo | |
| MX2024014591A (es) | Anticuerpo anti-bdca2 y uso del mismo | |
| BR112022020716A2 (pt) | Anticorpos anti-tumor associados ao antígeno e usos dos mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |